Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Intellipharmaceutics International Inc. (IPCIQ : OTC)

• Company Description    Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $ Daily Weekly Monthly 20 Day Moving Average: shares Shares Outstanding: 33.09 (millions) Market Capitalization: $ (millions) Beta: 52 Week High: $0.00 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week % % 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 30 WORCESTER ROAD - TORONTO,A6 M9W 5X2 CAN ph: 416-798-3001 fax: 416-798-3007 investors@intellipharmaceutics.com http://www.intellipharmaceutics.com

• General Corporate Information    Officers Isa Odidi - Chief Executive Officer and Chairman Amina Odidi - President; Chief Operating Officer and Chief Finan Patrick Yat - Vice-President Norman Betts - Director Shawn Graham - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 458173309 SIC: 2834 Fiscal Year Fiscal Year End: November Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 33.09 Most Recent Split Date: 9.00 (0.10:1) Beta: Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: % Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 05/31/25 - - 02/28/25 - - 11/30/24 - - ROA 05/31/25 - - 02/28/25 - - 11/30/24 - - Current Ratio 05/31/25 - - 02/28/25 - - 11/30/24 - - Quick Ratio 05/31/25 - - 02/28/25 - - 11/30/24 - - Operating Margin 05/31/25 - - 02/28/25 - - 11/30/24 - - Net Margin 05/31/25 - - 02/28/25 - - 11/30/24 - - Pre-Tax Margin 05/31/25 - - 02/28/25 - - 11/30/24 - - Book Value 05/31/25 - - 02/28/25 - - 11/30/24 - - Inventory Turnover 05/31/25 - - 02/28/25 - - 11/30/24 - - Debt-to-Equity 05/31/25 - - 02/28/25 - - 11/30/24 - - Debt-to-Capital 05/31/25 - - 02/28/25 - - 11/30/24 - -

Powered by Zacks Investment Research ©